Extended surgical resection in stage III non-small cell lung cancer
- PMID: 19955797
- DOI: 10.1159/000262466
Extended surgical resection in stage III non-small cell lung cancer
Abstract
Stage III includes a large variety of clinical situations from chest wall invasion together with intralobar lymph node metastasis to any size of a lung cancer in combination with mediastinal lymph node involvement (N2/N3). Furthermore, the prognosis of patients with lymph node metastasis depends largely on the extent of the disease, which may range from micro-metastasis occasionally found during surgery to bulky and/or multilevel involvement of the mediastinum or extracapsular infiltration. Not surprising the optimal treatment including the role of surgery for stage IIIA (N2) and stage IIIB (T4/N3) non-small cell lung cancer is discussed controversially. Adequate analysis of the clinical stage is key to select the best treatment. In general, patients benefit from surgery, when a radical resection can be achieved with a low morbidity and mortality. A multidisciplinary approach is indicated in most patients, which present with stage III disease at diagnosis. Preferentially patients should be treated in study protocols whenever they are available. Radical surgery including chest wall resection may result in a 5-year survival rate of up to 50% in T3N1 disease. Adjuvant chemotherapy is recommended and radiotherapy is reserved for cases with unclear resection margins. Clinical trials of preoperatively proven N2 patients could show a better outcome when downstaging is achieved after neoadjuvant chemo- or chemoradiotherapy prior to surgery. Patients who may need a pneumonectomy should be selected with caution since some centers experience a high perioperative mortality rate. If unforeseen N2 disease is found during surgery, an adjuvant therapy is recommended. Patients with T4 tumors (infiltration of great vessels, trachea, esophagus, vertebral bodies, etc.) show an increasing 5-year survival from 15 to 35% after radical resection with acceptable perioperative mortality if treated in experienced centers. In stage III non-small cell lung cancer, surgery should be performed within a multimodality approach. Surgery should be recommended when resection is radical including systematic lymph node dissection and mortality and morbidity are low.
Copyright 2010 S. Karger AG, Basel.
Similar articles
-
Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.Eur J Cardiothorac Surg. 2009 Sep;36(3):433-9. doi: 10.1016/j.ejcts.2009.04.013. Epub 2009 Jun 6. Eur J Cardiothorac Surg. 2009. PMID: 19502079
-
[Multimodal treatment of non small cell lung cancer].Zentralbl Chir. 2006 Apr;131(2):110-4. doi: 10.1055/s-2006-921534. Zentralbl Chir. 2006. PMID: 16612776 German.
-
Surgical therapeutic strategy for non-small cell lung cancer with mediastinal lymph node metastasis (N2).Zhongguo Fei Ai Za Zhi. 2010 Apr;13(4):342-8. doi: 10.3779/j.issn.1009-3419.2010.04.14. Zhongguo Fei Ai Za Zhi. 2010. PMID: 20677562 Free PMC article.
-
The present status of surgery for lung cancer.Acta Chir Belg. 1996 Nov-Dec;96(6):245-51. Acta Chir Belg. 1996. PMID: 9008764 Review.
-
Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement.Thorac Surg Clin. 2008 Nov;18(4):403-15. doi: 10.1016/j.thorsurg.2008.07.004. Thorac Surg Clin. 2008. PMID: 19086609 Review.
Cited by
-
Surgical strategies in the therapy of non-small cell lung cancer.World J Clin Oncol. 2014 Oct 10;5(4):595-603. doi: 10.5306/wjco.v5.i4.595. World J Clin Oncol. 2014. PMID: 25302164 Free PMC article. Review.
-
Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy.BMC Cancer. 2019 May 22;19(1):478. doi: 10.1186/s12885-019-5692-3. BMC Cancer. 2019. PMID: 31113432 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical